Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28394070 | 0.92 | ESR1 (0.36) | ESR1ESR2NR1I2ADRA2AADRA2B | |
| SCHEMBL817069 | 0.91 | ESR1 (0.42) | ESR1ESR2GRIA4 | |
| SCHEMBL29288755 | 0.88 | NR1I2 (0.46) | ESR1ESR2NR1I2ADRA2AADRA2B | |
| SCHEMBL816075 | 0.86 | ADRA2A (0.42) | ESR1ESR2NR1I2ADRA2AADRA2B | |
| SCHEMBL6162603 | 0.84 | NR1I2 (0.55) | ESR1ESR2NR1I2 | |
| SCHEMBL28140502 | 0.84 | NR1I2 (0.55) | ESR1ESR2NR1I2 | |
| SCHEMBL28031202 | 0.83 | ESR1 (0.38) | ESR1ESR2NR1I2 | |
| SCHEMBL8859009 | 0.82 | NR1I2 (0.41) | ESR1ESR2NR1I2 | |
| SCHEMBL6850756 | 0.80 | NR1I2 (0.44) | ESR1ESR2NR1I2 | |
| SCHEMBL5480284 | 0.80 | NR1I2 (0.44) | ESR1ESR2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212348-B2 | Method for producing hematopoietic stem cells using pyrazole compounds | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-12-15 | — | — | US | claimed |
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | claimed |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-10-11 | — | — | US | claimed |
| CN-102666490-A | Aminopyridine compound | UBE INDUSTRIES | 2012-09-12 | — | — | CN | claimed |
| EP-2520570-A1 | AMINOPYRIDINE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-10-11 | — | — | US | disclosed |
| CN-102666490-A | Aminopyridine compound | UBE INDUSTRIES | 2012-09-12 | — | — | CN | disclosed |
| EP-0888262-B1 | CYCLOALKYL DERIVATIVES AND THE SOLID-PHASE SYNTHESIS OF SUCH DERIVATIVES | BASF AG (DE) | 2004-06-02 | — | — | EP | disclosed |
| CN-1140485-C | Cycloalkyl derivatives and solid-phase synthesis thereof | BASF | 2004-03-03 | — | — | CN | disclosed |
| CN-1131233-C | Carbohydrate derivatives and their solid-phase synthesis | BASF AG (DE) | 2003-12-17 | — | — | CN | disclosed |
| US-6521780-B1 | Cycloalkylmalonic ester derivatives as potential active substances in the drugs and crop protection; combinatorial chemistry | BASF AKTIENGESELLSCHAFT (DE) | 2003-02-18 | — | — | US | disclosed |
| EP-0906324-B1 | CARBOHYDRATE DERIVATIVES AND THEIR SOLID-PHASE SYNTHESIS | BASF AG (DE) | 2001-08-01 | — | — | EP | disclosed |
| US-6242583-B1 | COUPLING CARBOHYDRATE COMPOUNDS IN PRESENCE OF PROMOTER TO A FUNCTIONALIZED SOLID SUPPORT | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-05 | — | — | US | disclosed |
| CN-1219937-A | Carbohydrate derivatives and their solid-phase synthesis | BASF AG (DE) | 1999-06-16 | — | — | CN | disclosed |
| CN-1218448-A | Cycloalkyl derivatives and solid-phase synthesis thereof | BASF AG (DE) | 1999-06-02 | — | — | CN | disclosed |
| EP-0906324-A1 | CARBOHYDRATE DERIVATIVES AND THEIR SOLID-PHASE SYNTHESIS | BASF AKTIENGESELLSCHAFT (DE) | 1999-04-07 | — | — | EP | disclosed |
| EP-0888262-A1 | CYCLOALKYL DERIVATIVES AND THE SOLID-PHASE SYNTHESIS OF SUCH DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997045436-A1 | CARBOHYDRATE DERIVATIVES AND THEIR SOLID-PHASE SYNTHESIS | BASF AKTIENGESELLSCHAFT (DE) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997034852-A1 | CYCLOALKYL DERIVATIVES AND THE SOLID-PHASE SYNTHESIS OF SUCH DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259123-A1 | AMINOPYRIDINE COMPOUND | PTGIS, QDPR, PTGIR | ESR1 4791/4885ESR2 4671/4885NR1I2 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.